Author: Rafael Banares

1.

Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis

Trebicka J, Aguilar F, Farias A, Lozano J, Sanchez-Garrido C, Uson-Raposo E, et al.

Gut . 2025 Feb; PMID: 40011033

Background And Aims: Quantifying systemic inflammation (SI) in acutely decompensated cirrhosis (ADC) is of major importance because SI is a driver of the most severe forms of ADC, including acute-on-chronic...

2.

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial

Pose E, Jimenez C, Zaccherini G, Campion D, Piano S, Uschner F, et al.

JAMA . 2025 Feb; 333(10):864-874. PMID: 39908052

Importance: There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis. Objective: To assess whether...

3.

Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis

Diaz-Ruiz R, Poca M, Roman E, Panadero-Gomez R, Cuyas B, Banares I, et al.

Nutrients . 2025 Jan; 17(2. PMID: 39861356

Decompensated cirrhosis is characterized by systemic inflammation and innate and adaptive immune dysfunction. Hepatic encephalopathy (HE) is a prevalent and debilitating condition characterized by cognitive disturbances in which ammonia and...

4.

Progressive systemic inflammation precedes decompensation in compensated cirrhosis

Sanchez-Aldehuelo R, Villanueva C, Genesca J, Garcia-Pagan J, Castillo E, Calleja J, et al.

JHEP Rep . 2025 Jan; 7(2):101231. PMID: 39850960

Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and...

5.

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

Semmler G, Alonso Lopez S, Pons M, Lens S, Dajti E, Griemsmann M, et al.

Hepatology . 2025 Jan; 81(2):609-624. PMID: 39817915

Background And Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and...

6.

Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd)

Albillos A, Banares R, Hernandez-Gea V

Gastroenterol Hepatol . 2025 Jan; 48(1):502208. PMID: 39756832

Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis,...

7.

Loss of protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

Lamas-Paz A, Hionides-Gutierrez A, Guo F, Jorquera G, Moran-Blanco L, Benede-Ubieto R, et al.

JHEP Rep . 2024 Dec; 7(1):101230. PMID: 39659733

Background & Aims: Expression of P21, encoded by the gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present...

8.

Dynamics of Ischemia/Reperfusion Injury Markers During Normothermic Liver Machine Perfusion

Caballero-Marcos A, Rodriguez-Bachiller L, Baroja-Mazo A, Morales A, Fernandez-Caceres P, Fernandez-Martinez M, et al.

Transplant Direct . 2024 Nov; 10(12):e1728. PMID: 39553741

Background: A comprehensive mechanistic assessment of normothermic machine perfusion (NMP) is an essential step toward identifying biomarkers to assess liver viability. Although some studies have evaluated the effect of NMP...

9.

Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd)

Albillos A, Banares R, Hernandez-Gea V

Rev Esp Enferm Dig . 2024 Oct; 117(1):14-57. PMID: 39350672

Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis,...

10.

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

Tellez L, Rincon D, Payance A, Jaillais A, Lebray P, Rodriguez de Santiago E, et al.

J Hepatol . 2024 Sep; 82(3):480-489. PMID: 39260705

Background & Aims: Fontan-type surgery is a palliative procedure for congenital heart disease with univentricular physiology that may, in the long term, lead to advanced chronic liver disease. Herein, we...